Ahva Shahabi, PhD, MPH
Dr. Shahabi has extensive experience in statistical analysis, and conducts management, analytic design and execution of a wide range of research studies, including epidemiologic, clinical and translational, and health economic studies. She has worked with several types of data sources including clinical and hospital registry data, administrative claims, and has generated and used genetic data for large cohorts. Prior to working at PHE, she performed and managed research within interdisciplinary teams at the Keck School of Medicine of USC and USC/Norris Comprehensive Cancer Center exploring the roles of genes, environment, and their interactions on disease risk and prognosis in both clinical and laboratory settings. She managed the initiation and maintenance of an NIH-funded correlative study involving a nationwide multi-center Phase III clinical trial used to determine biomarkers of hormone therapy response and disease progression in advanced prostate cancer patients. She received funding from the NIH as a pre-doctoral candidate to develop a novel gene expression signature predictive of clinical recurrence in localized prostate cancer patients. Dr. Shahabi has over 25 peer-reviewed publications, abstracts, and presentations.
PhD, Molecular Epidemiology
MPH, Epidemiology and Biostatistics, University of Southern California
BS, Health Promotion and Disease Prevention, University of Southern California
- Eeles, RA, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics 2013.
- Shahabi, A, et al. Genetic admixture and risk of hypertensive disorders of pregnancy among Latinas in Los Angeles County. Epidemiology 2013.
- Shahabi, A, et al. Tobacco smoking, polymorphisms in carcinogen metabolism enzyme genes, and risk of localized and advanced prostate cancer: results from the California Collaborative Prostate Cancer Study. Cancer Medicine 2014.
- Shahabi, A, et al. Novel gene expression signature predictive of clinical recurrence after radical prostatectomy in early stage prostate cancer patients. The Prostate 2016.